Phase 2 Results of BIIB080, a Novel Tau-Targeting Drug

Biogen (BIIB) and Ionis (IONS) have announced the results of the Phase 2 'CELIA' study for BIIB080 (diranersen), a tau-targeting Alzheimer's disease treatment candidate. BIIB080 is an antisense oligonucleotide (ASO) therapy designed to inhibit the expression of MAPT mRNA, which encodes for the tau protein, thereby preventing the abnormal accumulation of tau in brain cells. In the 18-month study involving early Alzheimer's patients, all three dosage groups showed a trend toward efficacy in slowing cognitive decline compared to the placebo group. Notably, the lowest dose group achieved a 26% reduction in the rate of decline based on the CDR-SB (Clinical Dementia Rating-Sum of Boxes) scale.

Failure to Demonstrate Linear Dose-Response and Underlying Analysis

However, the trial failed to demonstrate a 'linear dose-response relationship,' where higher doses lead to greater efficacy, thus failing to meet the primary endpoint. This was due to the observation that the highest dose group showed a lower rate of cognitive improvement compared to the low-dose group. This suggests that the drug's pharmacokinetic (PK) properties or the efficiency of drug delivery to brain cells may have reached a saturation point. Optimizing the drug's dosage will be a key factor in determining appropriate administration convenience in the future commercialization process, and Biogen researchers will continue to conduct detailed analyses to elucidate the structural mechanisms of this data.

Paradigm Shift from Targeting Amyloid to Tau

Despite this, the industry views the data from BIIB080 as a significant milestone and a major technological turning point in the field of tau-targeting therapies. Eisai's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab), which have already been approved, target amyloid-beta plaques, but their efficacy in slowing cognitive decline is limited to about 27%. Directly inhibiting tau protein, which begins to cause symptoms after amyloid accumulates in the brain, may more fundamentally halt the progression of the disease. The 26% improvement shown by BIIB080 is comparable to amyloid-targeting therapies, demonstrating that tau inhibition has sufficient value as an early intervention therapy for Alzheimer's disease.

Biogen's Bold $580 Million Bet on Phase 3

Based on the cognitive improvement signals and tau reduction data, Biogen has decided to proceed to Phase 3 trials, despite the failure to meet the primary endpoint. Cantor Fitzgerald estimates that the total cost, including milestone payments to Ionis, will be approximately $580 million. This is an extension of the 2018 co-development agreement and the 2019 exercise of the exclusive license option for BIIB080 (an upfront payment of $45 million and milestone payments of $155 million). However, given the high failure rate of Alzheimer's drug development, there are concerns that this could be a high-risk investment.

Competitive Landscape and Regulatory Outlook for the Next-Generation Alzheimer's Market

If BIIB080 is commercialized, it will become the first-in-class tau inhibitor in the Alzheimer's market, which is expected to grow to $30 billion by 2035. By demonstrating efficacy earlier than competitors such as Denali Therapeutics (DNLI) and Arrowhead (ARWR), Biogen will gain a leading position in the market. In the future, the key challenge in Phase 3 trials will be to control the 'confusional states' observed in the high-dose group and establish a safe dosage for FDA approval.